Selective targeting of different populations of myeloid-derived suppressor cells by histone deacetylase inhibitors

Identification of monocyte-like precursors of granulocytes in cancer as a mechanism for accumulation of PMN-MDSCs

(2019) Jérôme Mastio et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells

(2019) Tessa Knox et al.   Scientific Reports

Myeloid-derived suppressor cells coming of age

(2018) Filippo Veglia et al.   NATURE IMMUNOLOGY

The role of myeloid-derived suppressor cells in chronic infectious diseases and the current methodology available for their study

(2018) Hernán F. Peñaloza et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs

(2018) Brian J. Christmas et al.   Cancer Immunology Research

Myeloid-derived suppressor cells: Important contributors to tumor progression and metastasis

(2017) Elham Safarzadeh et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Myeloid-Derived Suppressor Cells

(2017) Dmitry I. Gabrilovich   Cancer Immunology Research

Histone deacetylase inhibitors as immunomodulators in cancer therapeutics

(2016) Li Shen et al.   Epigenomics

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards

(2016) Vincenzo Bronte et al.   Nature Communications

The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat

(2016) Yusuke Tomita et al.   OncoImmunology

Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition

(2015) Stephen Mok et al.   BMC CANCER

Drafting the proteome landscape of myeloid-derived suppressor cells

(2015) María Gato et al.   PROTEOMICS

HDAC inhibitors and immunotherapy; a double edged sword?

(2015) Michiel Kroesen et al.   Oncotarget

Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells

(2014) Fengdong Cheng et al.   MOLECULAR IMMUNOLOGY

Inhibition of CSF-1R Supports T-Cell Mediated Melanoma Therapy

(2014) Marjolein Sluijter et al.   PLoS One

CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+T cells

(2014) Debbie C Strachan et al.   OncoImmunology

Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses

(2012) J. B. Mitchem et al.   CANCER RESEARCH

Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models

(2012) Li Shen et al.   PLoS One

An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation

(2010) K. P. A. MacDonald et al.   BLOOD